PARP1 and breast carcinoma: The current study showed an enhanced cytotoxic effect of the combination of human PARP inhibitors (olaparib) and human Akt inhibitors (capivasertib) in TNBC breast cancer cell line models and MCF7 cells (Figure 1a,b).